The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study.
COVID-19
/ diagnostic imaging
Convalescence
Electrocardiography
Heart
/ diagnostic imaging
Heart Diseases
/ diagnostic imaging
Host-Pathogen Interactions
Humans
Kidney
/ diagnostic imaging
Kidney Diseases
/ diagnostic imaging
Longitudinal Studies
Lung
/ diagnostic imaging
Multimodal Imaging
Predictive Value of Tests
Prospective Studies
Research Design
SARS-CoV-2
/ pathogenicity
Scotland
Time Factors
Biomarkers
Imaging
Myocardial infarction
Myocardial inflammation
Myocardial injury
SARS-CoV-2
Journal
Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
12
06
2020
accepted:
17
07
2020
pubmed:
24
7
2020
medline:
15
12
2020
entrez:
24
7
2020
Statut:
ppublish
Résumé
COVID-19 is typically a primary respiratory illness with multisystem involvement. The prevalence and clinical significance of cardiovascular and multisystem involvement in COVID-19 remain unclear. This is a prospective, observational, multicentre, longitudinal, cohort study with minimal selection criteria and a near-consecutive approach to screening. Patients who have received hospital care for COVID-19 will be enrolled within 28 days of discharge. Myocardial injury will be diagnosed according to the peak troponin I in relation to the upper reference limit (URL, 99th centile) (Abbott Architect troponin I assay; sex-specific URL, male: >34 ng/L; female: >16 ng/L). Multisystem, multimodality imaging will be undertaken during the convalescent phase at 28 days post-discharge (Visit 2). Imaging of the heart, lung, and kidneys will include multiparametric, stress perfusion, cardiovascular magnetic resonance imaging, and computed tomography coronary angiography. Health and well-being will be assessed in the longer term. The primary outcome is the proportion of patients with a diagnosis of myocardial inflammation. CISCO-19 will provide detailed insights into cardiovascular and multisystem involvement of COVID-19. Our study will inform the rationale and design of novel therapeutic and management strategies for affected patients. ClinicalTrials.gov identifier NCT04403607.
Sections du résumé
BACKGROUND
COVID-19 is typically a primary respiratory illness with multisystem involvement. The prevalence and clinical significance of cardiovascular and multisystem involvement in COVID-19 remain unclear.
METHODS
This is a prospective, observational, multicentre, longitudinal, cohort study with minimal selection criteria and a near-consecutive approach to screening. Patients who have received hospital care for COVID-19 will be enrolled within 28 days of discharge. Myocardial injury will be diagnosed according to the peak troponin I in relation to the upper reference limit (URL, 99th centile) (Abbott Architect troponin I assay; sex-specific URL, male: >34 ng/L; female: >16 ng/L). Multisystem, multimodality imaging will be undertaken during the convalescent phase at 28 days post-discharge (Visit 2). Imaging of the heart, lung, and kidneys will include multiparametric, stress perfusion, cardiovascular magnetic resonance imaging, and computed tomography coronary angiography. Health and well-being will be assessed in the longer term. The primary outcome is the proportion of patients with a diagnosis of myocardial inflammation.
CONCLUSION
CISCO-19 will provide detailed insights into cardiovascular and multisystem involvement of COVID-19. Our study will inform the rationale and design of novel therapeutic and management strategies for affected patients.
CLINICAL TRIAL REGISTRATION
ClinicalTrials.gov identifier NCT04403607.
Identifiants
pubmed: 32702087
pii: 5875604
doi: 10.1093/cvr/cvaa209
pmc: PMC7454350
doi:
Banques de données
ClinicalTrials.gov
['NCT04403607']
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2185-2196Subventions
Organisme : Chief Scientist Office
ID : COV/GLA/20/05
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19026
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014/9
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Eur Heart J. 2020 May 14;41(19):1810-1817
pubmed: 32388565
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Eur Heart J. 2020 Apr 1;41(32):3106
pubmed: 32391885
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Eur Heart J Cardiovasc Imaging. 2020 Jul 1;21(7):709-714
pubmed: 32391912
JAMA Cardiol. 2020 Jul 1;5(7):819-824
pubmed: 32219357
Eur Heart J. 2005 Feb;26(4):369-75; discussion 322-4
pubmed: 15671045
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Am J Clin Pathol. 2020 May 5;153(6):725-733
pubmed: 32275742
Radiology. 2018 Sep;288(3):682-691
pubmed: 29989514
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
J Physiol. 2011 Feb 15;589(Pt 4):939-51
pubmed: 21173078
Cardiovasc Res. 2020 May 1;116(6):1097-1100
pubmed: 32227090
JACC Cardiovasc Imaging. 2012 Feb;5(2):154-66
pubmed: 22340821
JACC Cardiovasc Imaging. 2018 May;11(5):697-707
pubmed: 29454767
Postgrad Med J. 2006 Feb;82(964):140-4
pubmed: 16461478
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Circulation. 2020 Apr 21;141(16):1282-1291
pubmed: 32078380
Curr Cardiol Rep. 2018 Mar 6;20(3):15
pubmed: 29511861
Eur Heart J. 2017 Sep 14;38(35):2649-2662
pubmed: 28655210
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
JAMA Cardiol. 2019 May 1;4(5):460-464
pubmed: 30879022
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Ann Intensive Care. 2019 Jul 1;9(1):74
pubmed: 31264042
Am J Cardiol. 1989 Sep 15;64(10):651-4
pubmed: 2782256
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Eur Heart J. 2019 Jan 14;40(3):237-269
pubmed: 30165617
J Psychosom Res. 2009 Jul;67(1):17-23
pubmed: 19539814
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
JAMA Cardiol. 2020 Jul 1;5(7):751-753
pubmed: 32219362
Hypertension. 2012 Feb;59(2):300-7
pubmed: 22184331
Nature. 2002 Jun 20;417(6891):822-8
pubmed: 12075344
J Clin Med. 2020 May 11;9(5):
pubmed: 32403217
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8258-63
pubmed: 12829792
J Virol. 2013 Jun;87(12):6604-14
pubmed: 23552422
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
J Am Coll Cardiol. 2018 Mar 6;71(9):969-979
pubmed: 29495996
JACC Cardiovasc Imaging. 2019 Oct;12(10):1958-1969
pubmed: 30772231
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
J Cardiovasc Magn Reson. 2020 Feb 24;22(1):17
pubmed: 32089132
Eur Heart J. 2020 May 14;41(19):1861-1862
pubmed: 32267502
Lancet Respir Med. 2020 Jul;8(7):681-686
pubmed: 32473124
Int J Behav Nutr Phys Act. 2011 Oct 21;8:115
pubmed: 22018588
Circulation. 2003 Oct 14;108(15):1798-803
pubmed: 14504188
Lancet. 2020 May 9;395(10235):1516
pubmed: 32334650
J Am Coll Cardiol. 2008 Jan 29;51(4):466-72
pubmed: 18222358
J Affect Disord. 2010 Apr;122(1-2):86-95
pubmed: 19616305
Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1270-6
pubmed: 18403726
Eur Heart J. 2021 Jan 7;42(2):206
pubmed: 32176300
Eur Heart J. 2020 May 14;41(19):1859
pubmed: 32282027
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Int J Cardiol. 2016 Oct 1;220:775-80
pubmed: 27394973
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499
J Med Virol. 2020 Jul;92(7):726-730
pubmed: 32221983